, Impact de l'utilisation du test Oncotype DX sur les décisions de chimiothérapie adjuvante dans le cancer du sein hormono-dépendant HER2 négatif : une expérience française Auteurs, Le manuscrit original a été soumis et est actuellement en révision dans la revue Bulletin du Cancer
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. sept, vol.26, issue.5, pp.8-30, 2015. ,
Discordance with local guidelines for adjuvant chemotherapy in breast cancer: reasons and effect on survival, Clin Breast Cancer, vol.11, issue.1, pp.46-51, 2011. ,
, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, vol.365, issue.9472, pp.1687-717, 2005.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol, vol.24, issue.23, pp.3726-3760, 2006. ,
Analyse coût efficacité d'un test prédictif de la chimiothérapie dans le cancer du sein (Oncotype DX) en France, Bull Cancer, vol.99, issue.10, pp.907-921, 2012. ,
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, vol.351, issue.27, pp.2817-2843, 2004. ,
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol, vol.11, issue.1, pp.55-65, 2010. ,
,
, Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer, N Engl J Med, vol.12, issue.2, p.11121, 2018.
, R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2005.
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study, Oncologist. août, vol.20, issue.8, 2015. ,
Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer, Eur J Cancer, vol.66, p.10413, 2016. ,
Oncotype DX® in breast cancer patients: clinical experience, outcome and follow-up-a case-control study, Arch Gynecol Obstet. févr, vol.297, issue.2, p.4437, 2018. ,
Impact d'un test de signature génomique en sénologie sur les décisions en réunion de concertation pluridisciplinaire: une expérience française, Gynecologie Obstetrique & Fertilite, vol.12, issue.43, p.7805, 2015. ,
Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology, Ann Surg Oncol, vol.25, issue.10, p.28849, 2018. ,
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial, Lancet Oncol. janv, vol.11, issue.1, p.5565, 2010. ,
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial, Breast Cancer Res Treat, vol.165, issue.3, p.57383, 2017. ,
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with nodepositive breast cancer in the genomic era, NPJ Breast Cancer, vol.4, p.27, 2018. ,
, Essai clinique cancer Sein/Sein clos aux inclusions
,
Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged <50 Years versus 50 Years, and Trends Over Time, Ann Surg Oncol, vol.25, issue.10, p.287583, 2018. ,
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. sept, vol.26, issue.5, 2015. ,
Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients, Breast. août, vol.17, issue.4, p.32334, 2008. ,
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Res Treat. avr, vol.132, issue.3, p.895915, 2012. ,
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole, J Clin Oncol. 1 déc, vol.26, issue.34, p.556975, 2008. ,
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer, J Clin Oncol. 10 juin, vol.27, issue.17, p.280915, 2009. ,
Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in Turkey, J Breast Health. 1 juill, vol.12, issue.3, p.10711, 2016. ,
Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results, Breast Cancer Res Treat. févr, vol.168, issue.1, p.2934, 2018. ,
Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score, Hematol Oncol Stem Cell Ther. juin, vol.9, issue.2, p.4854, 2016. ,
Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay), Am J Clin Pathol. 1 juin, vol.147, issue.6, p.5418, 2017. ,
Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study, Br J Cancer. 28 juill, vol.113, issue.3, p.3905, 2015. ,